Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.64 |
| ▸ | ODC1 | P11926 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8069155 | 0.86 | ABCB1 (0.82) | KDM4EMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL26113703 | 0.85 | ABCB1 (0.65) | KDM4EPOLBMAPTRECQLCYP1A1 | |
| SCHEMBL29435852 | 0.85 | ABCB1 (0.65) | KDM4EPOLBMAPTRECQLCYP1A1 | |
| SCHEMBL31558902 | 0.85 | KDM4E (0.82) | KDM4EPOLBMAPTRECQLCYP1A1 | |
| SCHEMBL22686278 | 0.85 | KDM4E (0.82) | KDM4EPOLBMAPTRECQLCYP1A1 | |
| SCHEMBL28645437 | 0.83 | ABCB1 (0.76) | KDM4EPOLBMAPTCYP1A1CYP1B1 | |
| SCHEMBL34467579 | 0.83 | POLB (0.83) | KDM4EPOLBMAPTRECQLCYP1A1 | |
| Gradenin A SCHEMBL16894613 | 0.82 | KDM4E (0.92) | KDM4EPOLBMAPTRECQLCYP1A1 | |
| Gradenin A SCHEMBL29893822 | 0.82 | KDM4E (0.92) | KDM4EPOLBMAPTRECQLCYP1A1 | |
| SCHEMBL34468184 | 0.81 | CYP1B1 (1.00) | KDM4EPOLBMAPTRECQLCYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387561-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | COSTA RICAN SOCIAL SECURITY FUND / CAJA COSTARRICENSE DE SEGURO SOCIAL CCSS (CR) | 2022-12-08 | — | — | US | disclosed |
| US-11266968-B2 | Mineralizing biosurfactant used for nucleating silica | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-08 | — | — | US | disclosed |
| US-20220008519-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | US | disclosed |
| WO-2022008971-A2 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | WO | disclosed |
| EP-3046870-B1 | SILICA MICRO- AND NANO-CAPSULES AND METHODS FOR MAKING THEM | UNIV QUEENSLAND (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-20210093612-A1 | SYSTEMS AND METHODS TO TREAT PAIN LOCALLY | WARSAW ORTHOPEDIC INC (US) | 2021-04-01 | — | — | US | disclosed |
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2077821-B1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES | UNIV QUEENSLAND (AU) | 2019-08-14 | — | — | EP | disclosed |
| US-20190125826-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES ASSOCIATED WITH DESMOGLEIN-1 DEFICIENCY | INSERM INSTITUT NAT DE LA SANTE ET DE LA MEDICALE (FR) | 2019-05-02 | — | — | US | disclosed |
| US-20190083464-A1 | SYSTEMS AND METHODS TO TREAT PAIN LOCALLY | WARSAW ORTHOPEDIC, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-03 | — | — | US | disclosed |
| EP-2363122-A1 | Clonidine to treat pain locally | Medtronic, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20100159015-A1 | Systems and Methods to Treat Pain Locally | WARSAW ORTHOPEDIC, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100150895-A1 | Nutraceutical agent for attenuating the Neurodegenerative process associated with Parkinson's disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-17 | — | — | US | disclosed |
| EP-2043625-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | Medtronic, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008150899-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER AND INFLAMMATORY DISEASES | EMORY UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080292607-A1 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease | MAZZIO ELIZABETH | 2008-11-27 | — | — | US | disclosed |
| WO-2008014066-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | MEDTRONIC, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070116779-A1 | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease | MAZZIO ELIZABETH | 2007-05-24 | — | — | US | disclosed |
| US-20060253100-A1 | Systems and Methods to Treat Pain Locally | MEDTRONIC, INC. (US) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | TFAM, AIFM1, MAVS | KDM4E 4080/4885POLB 553/4885MAPT 2489/4885 |
| US-11266968-B2 | Mineralizing biosurfactant used for nucleating silica | SGMS2, PHOSPHO1, SOST | KDM4E 4686/4885POLB 927/4885MAPT 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.